Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Purchases $58,950.00 in Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The shares were bought at an average price of $11.79 per share, for a total transaction of $58,950.00. Following the completion of the purchase, the chief executive officer owned 9,005 shares of the company’s stock, valued at approximately $106,168.95. This represents a 124.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Seth Lederman also recently made the following trade(s):

• On Wednesday, March 18th, Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock. The shares were bought at an average price of $14.89 per share, for a total transaction of $223,350.00.

Tonix Pharmaceuticals Stock Down 2.8%

Shares of NASDAQ TNXP opened at $10.65 on Friday. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $10.03 and a fifty-two week high of $69.97. The firm’s 50-day simple moving average is $13.09 and its 200 day simple moving average is $14.95. The stock has a market cap of $169.76 million, a P/E ratio of -0.74 and a beta of 1.67.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Monday, May 11th. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. The company had revenue of $6.88 million for the quarter, compared to the consensus estimate of $6.13 million. On average, sell-side analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of TNXP. Legal & General Group Plc acquired a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at about $25,000. State of Wyoming acquired a new stake in Tonix Pharmaceuticals in the 4th quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new stake in Tonix Pharmaceuticals in the 3rd quarter valued at about $29,000. BNP Paribas Financial Markets acquired a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at about $65,000. Finally, Leonteq Securities AG acquired a new stake in Tonix Pharmaceuticals during the 4th quarter worth about $89,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Monday, April 20th. Finally, TD Cowen raised shares of Tonix Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tonix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.